Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, Samaneka W, Secours R, Van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Munyanga C, Chagomerana M, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC, Grinsztejn B; A5288 Study team. Avihingsanon A, et al. Among authors: kumarasamy n. J Int AIDS Soc. 2022 Jun;25(6):e25905. doi: 10.1002/jia2.25905. J Int AIDS Soc. 2022. PMID: 36039892 Free PMC article.
When to start antiretroviral therapy in resource-limited settings.
Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators. Walensky RP, et al. Ann Intern Med. 2009 Aug 4;151(3):157-66. doi: 10.7326/0003-4819-151-3-200908040-00138. Epub 2009 Jul 20. Ann Intern Med. 2009. PMID: 19620143 Free PMC article.
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J, Currier J, Wood R, Holmes CB, Pillay S, Conradie F, McIntyre J, Losina E, Walensky RP; CEPAC-International and OCTANE Investigators. Ciaranello AL, et al. AIDS. 2011 Feb 20;25(4):479-92. doi: 10.1097/QAD.0b013e3283428cbe. AIDS. 2011. PMID: 21293199 Free PMC article.
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Cohen MS, et al. Among authors: kumarasamy n. N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18. N Engl J Med. 2011. PMID: 21767103 Free PMC article. Clinical Trial.
Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.
Saravanan S, Vidya M, Balakrishnan P, Kantor R, Solomon SS, Katzenstein D, Kumarasamy N, Yeptomi T, Sivamalar S, Rifkin S, Mayer KH, Solomon S. Saravanan S, et al. Among authors: kumarasamy n. Clin Infect Dis. 2012 Apr;54(7):995-1000. doi: 10.1093/cid/cir967. Epub 2012 Feb 9. Clin Infect Dis. 2012. PMID: 22323567 Free PMC article.
Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.
Saravanan S, Madhavan V, Kantor R, Sivamalar S, Gomathi S, Solomon SS, Kumarasamy N, Smith DM, Schooley RT, Solomon S, Balakrishnan P. Saravanan S, et al. Among authors: kumarasamy n. AIDS Res Hum Retroviruses. 2012 Dec;28(12):1763-5. doi: 10.1089/AID.2011.0331. Epub 2012 May 21. AIDS Res Hum Retroviruses. 2012. PMID: 22404052 Free PMC article.
Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.
Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DA, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N. Bartlett JA, et al. Among authors: kumarasamy n. AIDS. 2012 Jul 17;26(11):1345-54. doi: 10.1097/QAD.0b013e328353b066. AIDS. 2012. PMID: 22441252 Free PMC article.
Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India.
Saravanan S, Madhavan V, Balakrishnan P, Smith DM, Solomon SS, Sivamalar S, Poongulali S, Kumarasamy N, Schooley RT, Solomon S, Kantor R. Saravanan S, et al. Among authors: kumarasamy n. AIDS Res Hum Retroviruses. 2013 Mar;29(3):630-2. doi: 10.1089/AID.2011.0334. Epub 2012 Dec 7. AIDS Res Hum Retroviruses. 2013. PMID: 23045961 Free PMC article.
Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children.
Bunupuradah T, Puthanakit T, Fahey P, Kariminia A, Yusoff NK, Khanh TH, Sohn AH, Chokephaibulkit K, Lumbiganon P, Hansudewechakul R, Razali K, Kurniati N, Huy BV, Sudjaritruk T, Kumarasamy N, Fong SM, Saphonn V, Ananworanich J; TApHOD. Bunupuradah T, et al. Among authors: kumarasamy n. Antivir Ther. 2013;18(4):591-8. doi: 10.3851/IMP2494. Epub 2013 Jan 7. Antivir Ther. 2013. PMID: 23296119 Free PMC article.
472 results